Company
3 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
AUG 14, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a REMS (Risk Evaluation and Mitigation Strategy) for an existing buprenorphine–naloxone combination product; this is a regulatory action, not a clinical trial, and does not report efficacy or safety data.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for fentanyl transdermal film products; this is a regulatory action, not a clinical trial, and does not report efficacy or safety trial outcomes.
JUN 8, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of estradiol transdermal film labeling; a regulatory action that does not report clinical trial outcomes or comparative efficacy data.